Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA-14069 MAD and DDI Study in Healthy Subjects and RA Patients
NCT05533372Phase 1Completed
- Sponsor
- ILAb Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IA-14069 in rheumatoid arthritis (RA) (3 arms), sponsored by ILAb Co., Ltd. Primary endpoint: Adverse Events at Day 35. Started Oct 2022; status: completed.
02
Drugs
IA-14069
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05533372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533372.